Open Access Maced J Med Sci electronic publication ahead of print, published on May 27, 2019 as https://doi.org/10.3889/oamjms.2019.134

ID Design Press, Skopje, Republic of Macedonia Open Access Macedonian Journal of Medical Sciences. https://doi.org/10.3889/oamjms.2019.134 elSSN: 1857-9655 **Case Report** 



# Spontaneous Clearance of Chronic HCV: The Key Ending Left in the Dark

Nikola Hristov Mumdzhiev, Daniela Valerieva Radicheva, Mariana Penkova Radicheva, Rumen Valchev Tenev, Zlatina Dimitrova Vasileva

UMHAT Prof. Stojan Kirkovitch, Stara Zagora, Bulgaria

#### Abstract

**BACKGROUND:** Hepatitis C is the second leading cause of liver cirrhosis and hepatocellular carcinoma. Although the discovery of direct-acting agents made the disease curable, HCV elimination can be achieved solely by the host's immunologic arsenal.

**CASE REPORT:** We report the case of a 29-year-old woman with chronic hepatitis C infection - elevated transaminases, positive serology. HCV was detectable on two occasions, and histology showed mild disease - A1F1. Upon follow up and without any treatment, the patient achieved spontaneous clearance confirmed by two consecutive undetectable HCV RNA tests. Spontaneous HCV clearance rarely occurs - 0.5% per person-year. This is sometimes accompanied by special circumstances like additional disease or medical interventions. Host factors like gender and interleukin-28B polymorphisms have been known to contribute to clearance. Viral factors like HCV RNA levels are also a factor. The characteristics of host-viral interplay – age of acquisition and fibrosis stage – cannot be overlooked.

**CONCLUSION:** All of the abovementioned factors contribute to the complex immunological interaction between virus and host and the result, although rarely can be spontaneous clearance.

Valideva Z. Spontaneous Clearance of Chronic HCV: The Key Ending Left in the Dark. Open Access Maced J Med Sci. https://doi.org/10.3889/camjms.2019.134 Keywords: Hepatitis C; spontaneous clearance; interferon free treatment

Citation: Hristov Mumdzhiev N, Valerieva Radicheva D, Penkova Radicheva M, Valchev Tenev R, Dimitrova

\*Correspondence: Nikola Hristov Mumdzhiev. UMHAT Stoqn Kirkocitch, Stara Zagora, Bulgaria. E-mail: niko\_mu2002@yahoo.com

Received: 18-Feb-2019; Revised: 05-Mar-2019; Accepted: 06-May-2019; Online first: 27-May-2019

Copyright: © 2019 Nikola Hristov Mumdzhiev, Daniela Valerieva Radicheva, Mariana Penkova Radicheva, Rumen Valchev Tenev, Zitana Dimitrova Vasileva. This is an open-access article distributed under the terms of the Creative Commons Artirbution-NonCommercial 4.0 International License (CC BY-NC 4.0)

Funding: This research did not receive any financial support

Competing Interests: The authors have declared that no competing interests exist

#### Introduction

Hepatitis C (HCV) is an enveloped, singlestranded RNA virus capable of causing acute and subsequent chronic infection [1] affecting mainly but not only the liver [2]. Although 20-40% of the acutely infected clear the virus spontaneously, about 75% of the individuals develop chronic infection [3]. Chronic HCV has a 170 million worldwide burden and is the second leading cause of liver cirrhosis and hepatocellular carcinoma [4].

The discovery of direct-acting agents, an undisputed breakthrough of modern medicine, has changed the course of the disease. The natural progression has given way to treatment with a nearto-100% success and a WHO Program for the worldwide elimination of HCV as a public health threat by 2030 [5]. Nevertheless, recovery can be achieved by the host's immunologic arsenal [6]. There's more to be found, as the mechanisms and predictors of spontaneous clearance in the chronic setting remain as blurred as the rarity of the event itself.

## **Case Report**

We report the case of a 29-year-old woman who presented to our clinic with an anti-HCV (+) positive test done 2 months earlier. The patient was unaware of her HCV infection. She has a history of intravenous drug use, currently on Methadone therapy and a sexual partner (also currently on Methadone therapy) with an HCV infection that was diagnosed at the same time as her diagnosis. She has no concomitant diseases or therapy and is a smoker. Further laboratory testing verified elevated transaminases (ASAT 386 IU/ml ALAT 740 IU/ml) and a low total bilirubin elevation 21.4  $\mu$ mol/l. No concomitant HBV or HIV infection was discovered. HCV RNA was 7 247 IU/ml, genotype 3. After four months she presented with normal transaminases and still detectable HCV RNA. This time the genotype was 1b. As per the national consensus for treating chronic viral hepatitis, a percutaneous liver biopsy was performed with an 18G true cut needle showing slight activity and fibrosis-METAVIR A1F1.

The unusual change in genotype arose some concerns, and before any treatment, a third HCV RNA test was done (nine months after the first one) with an undetectable result. Spontaneous clearance of chronic HCV RNA was discussed, and a last HCV RNA test was performed after 3 months (1 year after the initial) confirming the elimination.

## Discussion

Spontaneous elimination of chronic hepatitis C occurs rarely: a Scottish cohort demonstrating incidence of 0.19-0.36 per 100person-years [7]; a Japanese study demonstrated a clearance rate of one 0.5%/vear/person [8], and a third study placed the number at 0.75% per person-year (1.15 per 100person-years) in Alaska natives [9]. In most published cases loss of HCV RNA is associated with special circumstances like pregnancy and parturition [10], [11], [12], HBV superinfection [13], alcoholic hepatitis [14] or hepatocellular carcinoma [15]. Medical interventions can also alter the natural course of the disease - HCV clearance has been reported after surgery [16] including transplantation indicated for HCV cirrhosis [17] or the initiation of HAART for HIV co-infection [18]. Checkpoint inhibitors used in oncology show a promising effect when used in the setting of a concurrent chronic viral infection [19].

As in the presented case, perhaps more often than reported, HCV RNA is eliminated without any of the abovementioned events. Host (genetic) and virologic factors have been distinguished, influencing an interplay with several characteristics found to be clinically important. Female gender contributes to better prognosis in HCV infection, with HCV RNA rates hiaher for males than females [20]. Polymorphism on chromosome 19 - the interleukin-28B gene (IL28B) in particular the IL28B-CC genotype is associated with spontaneous clearance in the chronic setting. The latter is especially important in the setting of pregnancy/parturition [10] or HIV coinfection [18]. A genome-wide study detected an important polymorphism on chromosome 6-the HLA class II region near DQB1\*03:01 [21]. Although the study did distinguish between chronic not and acute spontaneous resolution, the gene has a role in chronic

disease. It has a higher incidence in patients who are asymptomatic carriers compared to those with HCV associated cirrhosis [22]. Younger age of infection is associated with a higher chance of spontaneous HCV clearance [7], [9]. Same can be said for the absence of significant fibrosis (evaluated by ultrasound) [8], although spontaneous elimination has been observed in the cirrhotic setting [14], [15]. There is a connection between the age of infection and fibrosis-younger age of HCV acquisition (< 40 years) is predictive of a slower progression to fibrosis [23]. As far as viral factors go, neither of the known genotypes has been associated with a higher rate of spontaneous clearance in the chronic setting, but low baseline HCV RNA is often discussed [6], [9].

The abovementioned "criteria", in which chronic HCV spontaneous elimination takes place, have their logical connection when looking into the immunology behind the events. Usually, an acute viral infection triggers a robust T-cell response. With antigenic clearance, immunological reactivity declines (protecting potential autoimmunity) and memory Tcells form [24]. In chronic infections, such as HCV, memory T-cells enter a state of exhaustion, unable to repeat the initial rapid response while antigens persist [25]. Up-regulation of PD-1 (programmed-death-1 receptor) on virus-specific T-cells marks and explains the state of exhaustion. The same receptor is influenced by the innovative checkpoint inhibitors used in cancer therapy [26]. PD-1 blockade improves T-cell proliferation, altering the state of exhaustion, and induces a significant reduction in HCV viremia [27], [28] even to a level below guantitation [28]. But T-cell exhaustion is not only medically reversible. Heterologous viral infections can also trigger the immune system [29]. Both alcohol consumption and parturition have been shown to induce a switch of responses [12], [14]. Humoral immune responses play a role in the decline of HCV RNA-neutralizing antibodies appears [30]. Despite the lack of clearance due to neutralising antibodies alone, there is a connection between them and the natural resolution of HCV [31].

The presented case and discussion perhaps only scratch the surface on the topic of spontaneous clearance in chronic HCV. Further work is required to uncover its true complex mechanisms. Nevertheless, the search continues. Despite the therapeutic success, true elimination will require more – a vaccine development [32].

## References

1. Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, Morris MD, Hajarizadeh B, Amin J, Cox AL, Kim AY. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014; 59(1):109-20. <u>https://doi.org/10.1002/hep.26639</u> PMid:23908124

#### PMCid:PMC3972017

2. Yan FM, Chen AS, Hao F, Zhao XP, Gu CH, Zhao LB, Yang DL, Hao LJ. Hepatitis C virus may infect extrahepatic tissues in patients with hepatitis C. World J Gastroenterol. 2000; 6(6):805-811. https://doi.org/10.3748/wjg.v6.i6.805 PMid:11819700 PMCid:PMC4728266

3. Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol. 2008; 103(5):1283-97. <u>https://doi.org/10.1111/j.1572-0241.2008.01825.x</u> PMid:18477352

4. Marcellin P, Kutala BK. Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int. 2018; 38(1):2-6. <u>https://doi.org/10.1111/liv.13682</u> PMid:29427496

5. World Health Organization. Global Hepatitis Repor, 2017.

 Lauer GM, Kim AY. Spontaneous resolution of chronic hepatitis C virus infection: are we missing something? Clin Infect Dis. 2006; 42(7):953-4. <u>https://doi.org/10.1086/500944</u> PMid:16511758

7. Bulteel N, Sarathy PP, Forrest E, Stanley AJ, Innes H, Mills PR, Valerio H, Gunson RN, Aitken C, Morris J, Fox R. Factors associated with spontaneous clearance of chronic hepatitis C virus infection. J Hepatol. 2016; 65(2):266-72. <u>https://doi.org/10.1016/j.jhep.2016.04.030</u> PMid:27155531

8. Watanabe H, Saito T, Shinzawa H, Okumoto K, Hattori E, Adachi T, Takeda T, Sugahara K, Ito JI, Saito K, Togashi H. Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: A population-based cohort study. J Med Virol. 2003; 71(1):56-61. <u>https://doi.org/10.1002/jmv.10448</u> PMid:12858409

9. Scott JD, McMahon BJ, Bruden D, Sullivan D, Homan C, Christensen C, Gretch DR. High rate of spontaneous negativity for hepatitis C virus RNA after establishment of chronic infection in Alaska Natives. Clinical infectious diseases. 2006; 42(7):945-52. <u>https://doi.org/10.1086/500938</u> PMid:16511757

10. Hashem M, Jhaveri R, Saleh DA, Sharaf SA, El-Mougy F, Abdelsalam L, Shardell MD, El-Ghazaly H, El-Kamary SS. Spontaneous viral load decline and subsequent clearance of chronic hepatitis C virus in postpartum women correlates with favorable interleukin-28B gene allele. Clinical Infectious Diseases. 2017; 65(6):999-1005. https://doi.org/10.1093/cid/cix445 PMid:28903504 PMCid:PMC6248538

11. Zein CO, Abu-Lebdeh H, Zein NN. Spontaneous clearance of chronic hepatitis C during pregnancy. The American journal of gastroenterology. 2001; 96(10):3044-5. <u>https://doi.org/10.1111/j.1572-0241.2001.04697.x</u> PMid:11693357

12. Hattori Y, Orito E, Ohno T, Sugauchi F, Suzuki S, Sugiura M, Suzumori K, Hattori K, Ueda R, Mizokami M. Loss of hepatitis C virus RNA after parturition in female patients with chronic HCV infection. Journal of medical virology. 2003; 71(2):205-11. https://doi.org/10.1002/jmv.10471 PMid:12938194

13. Sagnelli E, Coppola N, Pisaturo M, Masiello A, Tonziello G, Sagnelli C, Messina V, Filippini P. HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology. 2009; 49(4):1090-7. https://doi.org/10.1002/hep.22794 PMid:19263473

14. Silva MJ, Calinas F. Spontaneous clearance of hepatitis C virus during alcoholic hepatitis: the alcohol killed the virus? BMJ case reports. 2015; 2015:bcr2015211896. <u>https://doi.org/10.1136/bcr-2015-211896</u> PMid:26483390 PMCid:PMC4611481

15. Minami T, Tateishi R, Shiina S, Fujiwara N, Mikami S, Sato M, Uchino K, Enooku K, Asaoka Y, Kondo Y, Yoshida H. Spontaneous clearance of serum hepatitis C virus RNA during the clinical course of hepatocellular carcinoma in patients with chronic hepatitis C. Hepatology Research. 2014; 44(10):E32-7. https://doi.org/10.1111/hepr.12203 PMid:23841664

16. Yoshikawa M, Morimoto Y, Shiroi A, Yoshiji H, Kuriyama S, Fukui H. Spontaneous elimination of serum HCV-RNA after total gastrectomy for early gastric cancer in a patient with chronic hepatitis C. The American journal of gastroenterology. 2001; 96(3):922-3. https://doi.org/10.1111/j.1572-0241.2001.03650.x PMid:11280585

17. Samonakis DN, Cholongitas E, Triantos CK, Griffiths P, Dhillon AP,

Thalheimer U, Patch DW, Burroughs AK. Sustained, spontaneous disappearance of serum HCV-RNA under immunosuppression after liver transplantion for HCV cirrhosis. Journal of hepatology. 2005; 43(6):1091-3. <u>https://doi.org/10.1016/j.jhep.2005.08.005</u> PMid:16239045

18. Stenkvist J, Nyström J, Falconer K, Sönnerborg A, Weiland O. Occasional spontaneous clearance of chronic hepatitis C virus in HIVinfected individuals. Journal of hepatology. 2014; 61(4):957-61. https://doi.org/10.1016/j.jhep.2014.06.014 PMid:24951853

19. Davar D, et al. PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV. Case Rep Oncol Med. 2015; 2015;737389. https://doi.org/10.1155/2015/737389 PMid:26448890 PMCid:PMC4581502

20. Inoue G, et al. Hepatitis C virus clearance is prominent in women in an endemic area. J Gastroenterol Hepatol. 2000; 15(9):1054-8. https://doi.org/10.1046/j.1440-1746.2000.02276.x PMid:11059937

21. Duggal P, et al. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med. 2013; 158(4):235-45. <u>https://doi.org/10.7326/0003-4819-158-4-201302190-00003</u> PMid:23420232 PMCid:PMC3638215

22. Yoshizawa K, et al. Long-term follow-up of hepatitis C virus infection: HLA class II loci influences the natural history of the disease. Tissue Antigens. 2003; 61(2):159-65. <u>https://doi.org/10.1034/j.1399-0039.2003.00015.x</u> PMid:12694584

23. Poynard T, P. Bedossa, and P. Opolon, Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997; 349(9055):825-32. https://doi.org/10.1016/S0140-6736(96)07642-8

24. Masopust D, Schenkel JM. The integration of T cell migration, differentiation and function. Nature Reviews Immunology. 2013; 13(5):309. <u>https://doi.org/10.1038/nri3442</u> PMid:23598650

25. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015; 15(8):486-99. https://doi.org/10.1038/nri3862 PMid:26205583 PMCid:PMC4889009

26. Saeidi A, et al. T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses. Front Immunol. 2018; 9:2569. https://doi.org/10.3389/fimmu.2018.02569 PMCid:PMC6237934

27. Fuller MJ, et al. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci USA. 2013; 110(37):15001-6. https://doi.org/10.1073/pnas.1312772110 PMid:23980172

PMCid:PMC3773803

28. Gardiner D, et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One. 2013; 8(5):e63818. https://doi.org/10.1371/journal.pone.0063818 PMid:23717490 PMCid:PMC3661719

29. Welsh RM, Selin LK. No one is naive: the significance of heterologous T-cell immunity. Nat Rev Immunol. 2002; 2(6):417-26. https://doi.org/10.1038/nri820 PMid:12093008

30. Raghuraman S, et al. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis. 2012; 205(5):763-71. https://doi.org/10.1093/infdis/jir835 PMid:22293431 PMCid:PMC3274373

31. Ishii K, et al. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology. 1998; 28(4):1117-20. https://doi.org/10.1002/hep.510280429 PMid:9755251

32. Scott N, et al. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. BMC Med. 2015; 13:198. <u>https://doi.org/10.1186/s12916-015-0440-2</u> PMid:26289050 PMCid:PMC4546023